These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Randomised phase II study of standard versus chronomodulated CPT-11 plus chronomodulated 5-fluorouracil and folinic acid in advanced colorectal cancer patients. Garufi C; Vanni B; Aschelter AM; Zappalà AR; Bria E; Nisticò C; Sperduti I; Cognetti F; Terzoli E Eur J Cancer; 2006 Mar; 42(5):608-16. PubMed ID: 16246545 [TBL] [Abstract][Full Text] [Related]
3. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. Giacchetti S; Bjarnason G; Garufi C; Genet D; Iacobelli S; Tampellini M; Smaaland R; Focan C; Coudert B; Humblet Y; Canon JL; Adenis A; Lo Re G; Carvalho C; Schueller J; Anciaux N; Lentz MA; Baron B; Gorlia T; Lévi F; J Clin Oncol; 2006 Aug; 24(22):3562-9. PubMed ID: 16877722 [TBL] [Abstract][Full Text] [Related]
4. [Chronotherapy with high dose carboplatin, 5-fluorouracil and leucovorin in advanced colorectal carcinoma]. Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević A Srp Arh Celok Lek; 1998; 126(9-10):355-61. PubMed ID: 9863407 [TBL] [Abstract][Full Text] [Related]
5. Mitomycin-C, 5-fluorouracil, and leucovorin as a salvage therapy in patients with metastatic colorectal adenocarcinoma. Kang EJ; Choi YJ; Kim JS; Kim ST; Park KH; Choi IK; Oh SC; Seo JH; Shin SW; Kim JS; Kim YH Asia Pac J Clin Oncol; 2010 Dec; 6(4):286-91. PubMed ID: 21114778 [TBL] [Abstract][Full Text] [Related]
6. Chronotherapy with 5-fluorouracil, oxaliplatin, and folinic acid in colorectal cancer. Sandor V Lancet; 1997 Nov; 350(9087):1325-6. PubMed ID: 9357429 [No Abstract] [Full Text] [Related]
7. Tumori. Chronotherapy Study Group of the European Organization for Research and Treatment of Cancer. Garufi C; Dogliotti L; Terzoli E; Focan C; Smaaland R; Chollet P; Perpoint B; Lévi F Tumori; 1999; 85(2):149-50. PubMed ID: 10363085 [No Abstract] [Full Text] [Related]
8. The use cetuximab after oxaliplatin-based chemotherapy in a patient with metastatic colorectal cancer. Malik Z; Eng C Clin Adv Hematol Oncol; 2007 Jan; 5(1 Suppl 1):4-7. PubMed ID: 17491584 [No Abstract] [Full Text] [Related]
10. Revisiting the Cancer and Leukemia Group B/Southwest Oncology Group 80405 Trial: a phase III trial of chemotherapy and biologic agents for patients with untreated advanced colorectal adenocarcinoma. Venook AP; Blanke CD; Niedzwiecki D; Lenz HJ; Taylor JR; Hollis DR; Sutherland S; Goldberg RM Clin Colorectal Cancer; 2007 May; 6(7):536-8. PubMed ID: 17553204 [No Abstract] [Full Text] [Related]
11. Chemotherapy-free intervals in patients with metastatic colorectal cancer: a tale of two cities? Beretta GD; Scartozzi M; Tondulli L; Cascinu S J Clin Oncol; 2010 Jun; 28(16):e268-9; author reply e270. PubMed ID: 20385975 [No Abstract] [Full Text] [Related]
12. How to optimize the effect of 5-fluorouracil modulated therapy in advanced colorectal cancer. Ragnhammar P; Blomgren H Med Oncol; 1995 Sep; 12(3):187-201. PubMed ID: 8852401 [No Abstract] [Full Text] [Related]
13. The Roswell Park Memorial Institute and Gastrointestinal Tumor Study Group phase III experience with the modulation of 5-fluorouracil by leucovorin in metastatic colorectal adenocarcinoma. Petrelli NJ; Rustum YM; Bruckner H; Stablein D Adv Exp Med Biol; 1988; 244():143-55. PubMed ID: 3073651 [No Abstract] [Full Text] [Related]
14. Current role of bevacizumab in colorectal cancer. Saltz L Clin Adv Hematol Oncol; 2009 Jun; 7(6):375-6. PubMed ID: 19606071 [No Abstract] [Full Text] [Related]
16. Hepatic arterial infusion of chemotherapy for metastatic colorectal cancer. Lorenz M; Hochmuth K; Müller HH N Engl J Med; 2000 May; 342(20):1525-6; author reply 1526-7. PubMed ID: 10819651 [No Abstract] [Full Text] [Related]
17. Sequential 5-fluorouracil, methotrexate, and calcium leucovorin in metastatic colorectal cancer. Hansen RM; Banerjee TK; Davis HL; Zaentz SD; Schiferl EA; Ousley JL; Pogodzinski AE; Trump DL Wis Med J; 1988 May; 87(5):20-3. PubMed ID: 3291405 [No Abstract] [Full Text] [Related]
18. A Phase II trial of oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX4) as first-line chemotherapy in advanced colorectal cancer: a China single-center experience. Xu N; Fang WJ; Zhang XC; Yu LF; Bao HY; Shi GM; Huang S; Shen P Cancer Invest; 2007; 25(7):599-605. PubMed ID: 17882631 [TBL] [Abstract][Full Text] [Related]
19. Investigation into the usefulness and adverse events of CDDP, 5-fU and dl-leucovorin (PFL-therapy) for advanced colorectal cancer. Okabe S; Ishikawa T; Tanami H; Kuwabara H; Fukahara T; Udagawa M; Ootsukasa S; Arai T; Maruyama S; Murase N; Yamashita H; Iwai T J Med Dent Sci; 2002 Jun; 49(2):77-84. PubMed ID: 12627817 [TBL] [Abstract][Full Text] [Related]
20. Phase I trial of semustine plus weekly fluorouracil and high-dose leucovorin calcium in patients with advanced colorectal cancer. Abbruzzese JL; Weeks A; Raber MN; Gravel D; DuBrow RA; Levin B; Grem J; Chun HG J Natl Cancer Inst; 1989 Dec; 81(23):1840-2. PubMed ID: 2585532 [No Abstract] [Full Text] [Related] [Next] [New Search]